These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 18046972)

  • 1. The evolution of ACE inhibition--a turning point in cardiovascular medicine.
    Hedner T; Narkiewicz K; Kjeldsen SE
    Blood Press Suppl; 2007 Oct; 2():5-6. PubMed ID: 18046972
    [No Abstract]   [Full Text] [Related]  

  • 2. [Efficiancy Angiotensin -converting enzyme inhibitors for the clinical practice].
    Abuladze GV; Nebieridze MI; Narsiia EV; Erkomaishvili IG; Pipiia NG
    Georgian Med News; 2011 Jun; (195):37-40. PubMed ID: 21778538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. History of the design of captopril and related inhibitors of angiotensin converting enzyme.
    Cushman DW; Ondetti MA
    Hypertension; 1991 Apr; 17(4):589-92. PubMed ID: 2013486
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of the ACE inhibitor zofenopril in the treatment of ischemic heart disease.
    Buikema H
    Expert Rev Cardiovasc Ther; 2006 Sep; 4(5):631-47. PubMed ID: 17081085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of ACE-inhibitors in patients with recent myocardial infarction. Studies with zofenopril].
    Lombardi C; Castrini AI; Metra M; Carubelli V; Lazzarini V; Inama L; Dei Cas L
    G Ital Cardiol (Rome); 2012 Oct; 13(10 Suppl 2):55S-58S. PubMed ID: 23096377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ACE inhibition in acute myocardial infarction.
    Pfeffer MA
    N Engl J Med; 1995 Jan; 332(2):118-20. PubMed ID: 7990887
    [No Abstract]   [Full Text] [Related]  

  • 7. The discovery of captopril.
    Smith CG; Vane JR
    FASEB J; 2003 May; 17(8):788-9. PubMed ID: 12724335
    [No Abstract]   [Full Text] [Related]  

  • 8. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of the angiotensin-converting enzyme inhibitor, zofenopril, in the treatment of cardiovascular diseases.
    Borghi C; Bacchelli S; Degli Esposti D; Ambrosioni E
    Expert Opin Pharmacother; 2004 Sep; 5(9):1965-77. PubMed ID: 15330734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The discovery of captopril: a reply.
    Smith CG; Vane JR
    FASEB J; 2004 Jun; 18(9):935. PubMed ID: 15173103
    [No Abstract]   [Full Text] [Related]  

  • 11. Zofenopril after anterior myocardial infarction.
    Gurbel PA; O'Connor CM
    N Engl J Med; 1995 Jun; 332(25):1715. PubMed ID: 7619164
    [No Abstract]   [Full Text] [Related]  

  • 12. Zofenopril after anterior myocardial infarction.
    Chaudhry GM; Haneef N
    N Engl J Med; 1995 Jun; 332(25):1716. PubMed ID: 7760878
    [No Abstract]   [Full Text] [Related]  

  • 13. Zofenopril after anterior myocardial infarction.
    Mörike K; Mikus G
    N Engl J Med; 1995 Jun; 332(25):1715; author reply 1716. PubMed ID: 7760877
    [No Abstract]   [Full Text] [Related]  

  • 14. Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors.
    Borghi C; Boschi S; Ambrosioni E; Melandri G; Branzi A; Magnani B
    J Clin Pharmacol; 1993 Jan; 33(1):40-5. PubMed ID: 8429112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Utilization of angiotensin-converting enzyme inhibitors in anterior infarction without congestive semiology].
    de Teresa E
    Rev Esp Cardiol; 1995 May; 48(5):368. PubMed ID: 7792433
    [No Abstract]   [Full Text] [Related]  

  • 16. [ACE inhibitors after myocardial infarction: close-up on zofenopril].
    Teyssedou A
    Ann Cardiol Angeiol (Paris); 2007 Jun; 56(3):137-44. PubMed ID: 17482555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
    J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The problem of underdosing of angiotensin-converting enzyme inhibitors is markedly overrated: results from a study of patients discharged from hospital after an acute myocardial infarction.
    Kvan E; Reikvam A;
    Eur J Clin Pharmacol; 2004 May; 60(3):205-10. PubMed ID: 15034703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.
    Hansson L; Lindholm LH; Niskanen L; Lanke J; Hedner T; Niklason A; Luomanmäki K; Dahlöf B; de Faire U; Mörlin C; Karlberg BE; Wester PO; Björck JE
    Lancet; 1999 Feb; 353(9153):611-6. PubMed ID: 10030325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomized trial. The Captopril Prevention Project (CAPP) Study Group.
    Curr Hypertens Rep; 1999 Dec; 1(6):466-7. PubMed ID: 11041675
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.